Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors

Part of paid clinical trials in Richmond, California.

Sponsor
IntraAb, Inc.
Study ID
NCT07587879
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • mRNA-LNP — GENETIC
    intratumoral mRNA-LNP administration

Study Details

PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific antibody together with the immunostimulatory cytokines to kill tumors by recruited immune T cells.

Key Dates

Start date
Jan 1, 2027
Status verified
May 2026
Primary completion
Jan 1, 2030
Completion
Jan 1, 2031

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: all participants
    mRNA-LNP

Primary Outcome Measure

Number of participants with treatment-emergent adverse events (TEAEs) assessed by CTCAE v5. [ Time Frame: From first dose through Day 28 (±3 days) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
IntraAb Inc.RichmondCalifornia94806-

Find similar trials in Richmond, CA

By research site
IntraAb Inc.· Richmond, CA

Related Studies